Tod Reed Joins Lynch Regenerative Medicine as Strategic Advisor
14 August 2024 - 7:23PM
Business Wire
Reed is former Senior Vice President, U.S.
Sales and Sales Training, at Allergan Aesthetics at Abbvie
Tod Reed will join Lynch Regenerative Medicine, LLC (LRM) as a
Senior Strategic Advisor. Reed recently retired as the Senior Vice
President, U.S. Sales and Sales Training, at Allergan Aesthetics,
an Abbvie company.
Reed brings 37 years of experience with Allergan to the LRM
team, including more than 20 years in aesthetic and regenerative
medicine. During his tenure at Allergan Aesthetics, Reed was
responsible for helping build the largest sales organization in
U.S. medical aesthetics while helping launch iconic brands such as
Botox Cosmetic®, Juvederm®, and many other products in skin care,
body contouring and aesthetic surgery. He was also responsible in
the U.S. market for the renowned practice consulting group,
strategic accounts, sales force operations and the sales training
department.
“At LRM, we are building a leading regenerative medicine and
aesthetics company based on the most proven and trusted science in
the industry, combined with the some of the most experienced,
talented and trusted people in aesthetics and regenerative
medicine,” said Dr. Samuel Lynch, founder and CEO of LRM. “Tod’s
leadership at Allergan Aesthetics helped build it into the world’s
largest aesthetic medicine company. We welcome him to the LRM team,
where we strive every day to bring the best products together with
the best people to advance the regenerative medicine and aesthetics
fields.”
“I am humbled and excited to join Lynch Regenerative Medicine as
a strategic advisor,” said Reed. “The team is excellent, with years
of industry experience, and the product line both current and in
the future will bring needed enhancements to the growing markets
for aesthetics and regenerative medicine.”
LRM’s first product to improve skin aesthetics, Ariessence™ Pure
PDGF+ (www.ariessence.com), is available in leading innovative
med/spa clinics and other aesthetic-focused offices, including
dermatology and plastic surgery practices. Ariessence Pure PDGF+ is
used topically to improve aesthetic outcomes associated with
procedures such as micro-needling, dermabrasion, lasers, plastic
surgery and other procedures in which healthier-looking skin can be
accelerated and enhanced using growth factors such as PDGF.
“Growth factors play an important role in skin care today, but
no other solutions are backed by the high level of scientific and
clinical evidence that supports the safety and effectiveness of
pure PDGF in multiple regenerative treatments,” said Lynch.
“Ariessence Pure PDGF+ is based on this foundation of success in
regenerative medicine.”
About Lynch Regenerative Medicine, LLC
Lynch Regenerative Medicine, LLC is pioneering innovative
treatments that aim to revolutionize the $100 billion aesthetics
and wound-care markets. Our mission is to leverage our regenerative
medicine heritage and our decades-long commitment to safe and
effective regenerative products of the highest quality to deliver
exceptional results for our customers and their patients, thereby
redefining the future of aesthetic regenerative medicine. The
company was founded in 2023 and is based in Franklin,
Tennessee.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240814002316/en/
Nancy Rocco, n.rocco@lynchregen.com; 888-576-7343